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TransactivationCyclooxygenase-2 (COX-2), an endoplasmic reticulum-resident protein, has been known to promote
tumorigenesis, but the exact mechanisms involved have not been identiﬁed. We have previously reported
that COX-2 physically interacts with the tumor suppressor p53 and regulates its function. However, it
remains to be elucidated how COX-2 can interact with p53 residing in different compartments and whether
their interaction is involved in the regulation of p53 function. We here demonstrated that upon genotoxic
stress, COX-2 and p53 accumulate in the nucleus, where they physically interact with one another. We also
showed that an amino-terminal region (amino acids 1–126) of COX-2 interacts with the DNA-binding
domain of p53. The p53-interacting region was critical for COX-2-mediated inhibition of p53 DNA-binding
and transcriptional activity as well as p53- and genotoxic stress-induced apoptosis. In addition, an active site
mutant of COX-2 (S516Q) as well as wild-type COX-2 potently inhibited p53 transcriptional activity and
genotoxic stress-induced apoptosis. These results suggest that COX-2 principally inhibits p53 function
through a catalytic activity-independent mechanism and that COX-2 inhibits p53 function through a physical
interaction with p53 in the nucleus. These ﬁndings provide novel insight into the action mechanisms of COX-
2 and strongly suggest that the functional inactivation of p53 by COX-2 can be one of the mechanisms by
which COX-2 promotes tumorigenesis.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Prostaglandin endoperoxide H synthases, also known as cycloox-
ygenases (COXs), catalyze the conversion of arachidonic acid to
prostaglandin H2 (PGH2), the committed step in various prostanoid
biosyntheses. Two isozymes of COX have been identiﬁed: COX-1 is
usually responsible for basal and constitutive prostanoid synthesis,
whereas COX-2 is an inducible enzyme whose expression is increased
by various stimuli [1]. The primary subcellular location of COX-2 is the
endoplasmic reticulum (ER) and nuclear membranes. COX-2 contains
a signal sequence targeting the ER at the amino-terminus and an ER
retention signal at the carboxy-terminus [2]. By immunoelectron
microscopy, COX-2 is seen to be present on the luminal surfaces of the
ER and both the inner and outer nuclear membranes [3]. The major
end products of COX-2 catalytic activity are prostaglandin E2 (PGE2),
PGI2 and PGD2 [4].
Several lines of evidence indicate that COX-2 plays an important
role in tumorigenesis. First, expression levels of COX-2 are increased in
cancer tissues as compared to normal tissues in most human cancers
including bladder, breast, colon, liver, lung, prostate and stomach+82 33 250 8807.
ll rights reserved.cancers [5–9]. Second, COX-2 transgenic mice are known to develop
cancers such as breast or urinary bladder cancer [10,11]. Third,
tumorigenesis is inhibited in COX-2 knockout mice. For example, a
COX-2 knockout remarkably reduces the number and size of intestinal
polyps in ApcΔ716 knockout mice, a model of human familial
adenomatous polyposis (FAP) [12]. Fourth, COX-2 inhibitors have
shown potent anti-tumorigenic effects in both animal and human
studies. Selective COX-2 inhibitors such as celecoxib, rofecoxib and
nimesulide can inhibit tumorigenesis in animal models of breast,
colon, skin, stomach and urinary bladder cancer [13–20]. In addition,
celecoxib intake can reduce the incidence of polyp development in
FAP patients [21,22]. The mechanisms by which COX-2 promotes
tumorigenesis have been proposed and investigated in a variety of
cancers [23–25]. However, the precise mechanism by which COX-2
contributes to tumorigenesis remains largely unknown.
p53, the best-known tumor suppressor, is also the most frequently
inactivated tumor suppressor in human cancers. The p53 gene is
mutated in about half of all human cancers, and the p53 protein is
functionally inactivated in most of the remaining cases [26]. Following
DNA damage or activation of oncogenes, wild-type p53 translocates
from the cytosol to the nucleus and plays a critical role in inhibiting
cell proliferation by inducing cell cycle arrest, senescence or apoptosis.
The inhibitory effect of p53 on cell proliferation is largely dependent
on its activity as a transcription factor that binds to the consensus
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target genes. Among its target genes, p21Cip1/WAF1 has been known to
mediate cell cycle arrest, whereas Bax, DR5, IGF-BP3, NOXA, Pidd, PERP
and PUMA mediate p53-induced apoptosis [26,27].
Previously, we have reported that COX-2 is biochemically linked to
p53 and regulates its function. COX-2 has been shown to be a
downstream target gene of p53 and to be induced by p53-mediated
activation of the Ras/Raf/ERK pathway. DNA damaging agents
including doxorubicin, mitomycin C and γ-radiation induce the
expression of COX-2 in a p53-dependent manner [28]. Also, COX-2
inhibits p53- and genotoxic stress-induced apoptosis. Overexpression
of COX-2 is able to attenuate genotoxic stress-induced apoptosis in SK-
N-SH cells and human normal mammary epithelial cells (HMECs).
Apoptosis induced by p53 is signiﬁcantly enhanced in mouse
embryonic ﬁbroblasts (MEFs) that lack the COX-2 gene when
compared to that in COX-2 (+/+) MEFs. NS-398, a selective COX-2
inhibitor, potentiates genotoxic stress-induced apoptosis in human
primary epithelial cells, ﬁbroblasts and endothelial cells [28,29]. In
addition, COX-2 has been shown to inhibit p53 transcriptional activity
and to be able to physically interact with p53 in vitro and in vivo [29–
31]. These results suggest a possibility that COX-2 regulates p53
function through a physical interaction under genotoxic conditions.
However, it is still unclear how COX-2 can interact with p53 residing in
different compartments and whether their interaction is involved in
the regulation of p53 function.
In this study, we demonstrated that COX-2 colocalizes and
interacts with p53 in the nucleus under genotoxic stress. In addition,
we identiﬁed the interacting regions of COX-2 and p53, and showed
that COX-2 inhibits p53 function through the p53-interacting region.
Moreover, we presented evidence that COX-2 principally inhibits p53
function through a catalytic activity-independent mechanism by
using an active site mutant of COX-2 (S516Q). From these results,
we concluded that under genotoxic stress, COX-2 inhibits p53 function
mainly through a physical interaction in the nucleus.
2. Materials and methods
2.1. Cell culture
Saos-2 (human osteosarcoma), H1299 (human lung cancer), U2OS
(human osteosarcoma) cells, and human diploid ﬁbroblasts (HDFs)
were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM)
containing fetal bovine serum (10%) and penicillin/streptomycin
(1%) in a 5% CO2 incubator. Human normal mammary epithelial cells
(HMECs) were purchased from Cambrex and grown in DMEM/F12
containing supplements as described previously [32].
2.2. Plasmids and adenoviruses
An S516Q mutant of COX-2 was constructed using the Quick-
Change Site-Directed Mutagenesis kit (Stratagene). The forward
primer sequence was 5′-GTT GGA GCA CCA TTC CAG TTG AAA GGA
CTT ATG-3′ as described previously [33]. Mammalian expression
vectors for full-length or deletion mutants of COX-2 and p53 were
obtained by inserting PCR fragments of human COX-2 and p53 cDNAs
into pCS2-myc and pFlag-CMV-1 vectors. Bacterial expression vectors
for GST-COX-2 deletion mutants were cloned by inserting PCR
fragments of COX-2 cDNA into the pGEX-6p-2 vector. Adenoviruses
expressing GFP, COX-2, S516Q and myc-COX-2 deletion mutants were
generated and ampliﬁed as described previously [34].
2.3. PGE2 assays
The amount of PGE2 secreted into the culture medium was
determined by using an enzyme-linked immunosorbent assay kit
(Assay Designs).2.4. Luciferase reporter assays
Saos-2 cells were transfected with DNAs using Fugene 6 reagent
(Roche). β-galactosidase DNA was included in all experiments for
normalization of the transfection efﬁciency. Cell lysateswere prepared
48 h after transfection, and luciferase activities were measured using
the Luciferase assay kit (Promega).
2.5. Western blot analysis
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris–HCl, 1%
NP-40, 0.25% sodium deoxycholate, and 0.1% SDS) with 1 mM PMSF,
1 μg/ml leupeptin, 1 μg/ml aprotinin, and 1 μg/ml pepstatin. Proteins
were resolved on SDS-polyacrylamide gels and transferred to
nitrocellulose membranes, which were probed with speciﬁc anti-
bodies. The immunoreactive protein complexes were detected by
enhanced chemiluminescence (Amersham Bioscience). The speciﬁc
antibodies used in this study were: anti-COX-2 and anti-GFP
monoclonal antibodies purchased from BD Biosciences; anti-Flag
(M2) and anti-β-actin antibodies from Sigma; anti-p53 (Ab-6) and
anti-Mdm-2 (Ab-1) monoclonal antibodies from Oncogene Science;
anti-cleaved caspase-3, anti-p21 and anti-PARP antibodies from Cell
Signaling Technology; anti-GST and anti-SV40 large T (Pab 101)
antibodies from Santa Cruz Biotechnology; anti-Myc and anti-tubulin
antibodies from Covance.
2.6. GST pull-down assays
GST or GST-COX-2 deletion mutants were expressed in the E. coli
BL21 strain. Bacterial cell lysates were prepared by sonication and
mixed with 20 μl of glutathione-Sepharose 4B beads (Amersham) at
4 °C overnight. After collection by centrifugation, the beads were
mixed with mammalian cell lysates or recombinant human p53 (BD
Biosciences) for 2 h at 4 °C. The beads were collected and washed ﬁve
times. Bound proteins were then extracted and subjected to SDS-PAGE
followed by western blot analysis.
2.7. Immunoprecipitation assays
Cells were lysed in a lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1% NP-40, 0.25% sodium deoxycholate, 0.1% SDS, 50 mM NaF,
1 mM sodium orthovanadate, 1 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml
aprotinin and 1 μg/ml pepstatin) by passage through a 22G needle.
After centrifugation, cell lysates were immunoprecipitated with
speciﬁc antibodies at 4 °C, then mixed with Protein A agarose beads
(Upstate) for 2 h. The beads were collected, and precipitated proteins
were subjected to SDS-PAGE and western blot analysis.
2.8. FACS analysis
Cells were collected and resuspended in 1 ml cold PBS. Ethanol
pre-chilled at−20 °C was added drop-wise with periodic vortexing to
mix the cells. The resulting mixture was incubated at 4 °C overnight.
The following day, cells were washed with 10 ml ice-cold PBS and
permeabilized in a reagent consisting of 100 μg/ml RNase A and
50 μg/ml propidium iodide in PBS. Samples were incubated at 37 °C
for 1 h, then analyzed by ﬂow cytometry (Becton Dickinson FACScan).
The sub-G1 cell population was measured using the CellQuest
program.
2.9. Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts were prepared as described previously [35]. The
p53-binding double-stranded oligonucleotides, 5′-GGA CAT GCC CGG
GCA TGT CC-3′ [36], were labeled with 32P and incubated with 8 μg of
nuclear extracts for 1.5 h at 25 °C. In the case of some samples,
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Oncogene Science) were added to the mixture and incubated for a
further 15 min. The reaction mixtures were then subjected to
electrophoresis in nondenaturing polyacrylamide gels, which were
dried and exposed for autoradiography at −70 °C.
2.10. Subcellular fractionation
Cytoplasmic and nuclear fractions were prepared as described
previously [37]: Cells were washed with PBS and allowed to swell in
buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 1 mM DTT, 1 mM PMSF,
1 μg/ml leupeptin, 1 μg/ml aprotinin and 1 μg/ml pepstatin). After
15 min, cells were lysed by adding NP-40 (ﬁnal concentration, 0.5%)
and the nuclei were pelleted by centrifugation at 1500 ×g for 5 min.Fig. 1. COX-2 accumulates and interacts with p53 in the nucleus under conditions of genoto
indicated times. Cells were coincubated with anti-COX-2 and anti-p53 antibodies as describe
were treated with doxorubicin (1 μM), etoposide (0.1 μM), actinomycin D (25 ng/ml), PMA (
and subjected to western blot analysis. Nuclear COX-2 and p53 levels were quantitated by
nuclear protein, respectively. (D) COX-2 physically interacts with p53 in the nucleus. U2OS ce
fractions were prepared and analyzed by western blotting using antibodies against COX-2, p
treated U2OS cells (400 μg) were immunoprecipitated with an anti-p53 antibody (FL-393,
against COX-2 (BD Biosciences) and then p53 (Ab-6, Oncogene Science) (upper panels). Prot
precipitates were subjected to western blotting using antibodies against p53 (Ab-6) and thThe supernatant was centrifuged at 15,000 ×g for 5 min, and the
cytoplasmic fraction was recovered. The nuclei were washed with
buffer A and resuspended in buffer B (20 mM HEPES, pH 7.9, 0.4 M
NaCl, 1 mMDTT,1 mM PMSF, 1 μg/ml leupeptin, 1 μg/ml aprotinin and
1 μg/ml pepstatin). After incubation on ice for 15 min, the nuclear
fraction was recovered by centrifugation at 18,000 ×g for 5 min.
2.11. Confocal microcopy
Cells were seeded onto 18 mm coverslips and cultured over-
night. The following day, cells were treated with drugs for the
indicated periods of time, then ﬁxed in a 3.7% formaldehyde
solution. The cells were permeabilized in a 0.2% Triton X-100
solution and incubated simultaneously with anti-COX-2 monoclonalxic stress. HMECs (A) and U2OS cells (B) were exposed to doxorubicin (0.5 μM) for the
d in Materials and methods. Images were obtained with a confocal microscope. (C) HDFs
10 nM) or DMSO (the vehicle) for 8 h. Cytoplasmic and nuclear fractions were prepared
densitometry. Tubulin and PARP were used as controls for the cytoplasmic protein and
lls were treated or untreated with doxorubicin (0.5 μM) for 8 h. Cytoplasmic and nuclear
53, tubulin and PARP (left panels). Cytoplasmic and nuclear fractions from doxorubicin-
Santa Cruz), and the precipitates were subjected to western blotting using antibodies
eins were immunoprecipitated with an anti-COX-2 antibody (C-20, Santa Cruz), and the
en COX-2 (C-20) (lower panels).
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Biotechnology) antibodies. After 2 h, cells were washed and
incubated with TRITC-conjugated anti-mouse IgG and FITC-con-
jugated anti-rabbit IgG (Sigma). Images were taken with a confocal
microscope (Olympus Fluoview).
2.12. Statistical analysis
Comparison between two groups was made by the Student's t test
using the GraphPad Prism program (GraphPad Software). Differences
between groups were considered statistically signiﬁcant when the p
values were ≤0.05.
3. Results
3.1. COX-2 accumulates and interacts with p53 in the nucleus under
conditions of genotoxic stress
COX-2 is an endoplasmic reticulum (ER)-resident protein,
whereas p53 is known to shuttle between the cytosol and the
nucleus. To investigate how these two proteins residing in differentFig. 2. An amino-terminal region (amino acids 1–126) of COX-2 interacts with p53. (A) Sc
Identiﬁcation of the p53-interacting region of COX-2 using GST pull-down assays. U2OS cells w
pull-down experiments. The bead-bound proteins were analyzed by western blotting using a
by immunoprecipitation assay. U2OS cells were transfected with expression vectors for myc-
Immunoprecipitationwas carried out using an anti-myc antibody, and the bead-bound prote
of bead-bound myc-COX-2-M (∼50 kDa) was overlapped with the band of IgG heavy chains
region of COX-2. GST and GST-COX-2 deletion mutants were incubated with puriﬁed human p
proteins were subjected to western blotting with anti-p53 and anti-GST antibodies.compartments can physically interact with one another, we exam-
ined the subcellular localization of COX-2 and p53 under genotoxic
conditions.
Confocal microscopy showed that the majority of the COX-2 and
p53 molecules resided in the cytoplasm in resting human normal
mammary epithelial cells (HMECs) and U2OS cells. However, when
the cells were exposed to a genotoxic drug, doxorubicin, both COX-
2 and p53 accumulated in the nucleus, where they colocalized with
one another. A prominent nuclear accumulation of COX-2 and p53
was seen at 4 h and 8 h, respectively, after doxorubicin treatment
in both HMECs and U2OS cells, suggesting that COX-2 and p53
enter the nucleus independently (Fig. 1A and B). In the case of
human diploid ﬁbroblasts (HDFs), we observed by western blot
analysis that the levels of COX-2 and p53 were increased in the
nuclear fraction after treatment with various genotoxic drugs such
as doxorubicin, etoposide and actinomycin D. Treatment with
phorbol myristic acetate (PMA), a tumor promoter, also led to an
increase in the levels of COX-2 in the nuclear fraction, compatible
with a previous report [38] (Fig. 1C). These results suggest that
COX-2 and p53 accumulate and are colocalized in the nucleus in
response to genotoxic stimuli.hematic representation of the structure of COX-2 and the deletion mutants used. (B)
ere treatedwith doxorubicin (0.5 μM) for 8 h, and the cell lysateswere subjected to GST
ntibodies against p53 and GST. (C) Identiﬁcation of the p53-interacting region of COX-2
COX-2 deletion mutants as indicated and then treated with doxorubicin (0.5 μM) for 8 h.
ins were subjected towestern blotting with anti-p53 and anti-myc antibodies. The band
(53 kDa). (D) Direct interaction between COX-2 and p53 through the amino-terminal
53 protein (100 ng), and GST pull-down experiments were performed. The bead-bound
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under genotoxic conditions, we prepared cytoplasmic and nuclear
fractions from U2OS cells that had been treated or untreated with
doxorubicin for 8 h. Western blot analysis showed that COX-2 and
p53 accumulated in the nuclear fraction after doxorubicin treat-
ment, consistent with our confocal data (Fig. 1D, left panels).
Using the cytoplasmic and nuclear fractions from U2OS cells that
had been treated with doxorubicin, we carried out immunopreci-
pitation assays. The data showed that COX-2 was co-immunopre-
cipitated by an anti-p53 antibody from the nuclear fraction but
not from the cytoplasmic fraction (Fig. 1D, upper panels). Reverse
immunoprecipitation experiments using an anti-COX-2 antibody
also showed that p53 was co-immunoprecipitated from the
nuclear fraction but not from the cytoplasmic fraction (lower
panels). These results suggest that upon DNA damage, COX-2 andFig. 3. COX-2 interacts with the DNA-binding domain of p53. (A) Schematic representation o
binding domain; TD, tetramerization domain; BD, basic domain. (B and C) Identiﬁcation of th
COX-2, ﬂag-p53 deletionmutants or an empty vector (Vt) were transfected into H1299 cells a
the samples were then probed with anti-COX-2 and anti-ﬂag antibodies. In (C), immunopr
probed with anti-ﬂag and anti-COX-2 antibodies. (D) COX-2 interferes with the interaction b
LT (1 μg) and an increasing amount (0, 2.5 and 5 μg) of COX-2 were transfected into H1299
and the precipitated proteins were analyzed by western blotting with antibodies against p53
Expression vectors for p53 (1 μg), Mdm-2 (1 μg) and an increasing amount (0, 2.5 and 5 μg) o
out using an anti-Mdm-2 antibody, and the precipitated proteins were analyzed by western
binding activity of p53. Saos-2 cells were transfected with p53 and COX-2 cDNAs as indic
containing the p53 binding sequence. Unlabeled probes (cold probes) were added as a mixt
not decrease p53 protein levels or sequester p53 in the cytoplasm. Saos-2 cells were transfect
indicated. The p53 protein levels were analyzed by western blotting in whole cell lysate (W
cytoplasmic protein and nuclear protein, respectively.p53 accumulate in the nucleus, where they physically interact with
one another.
3.2. An amino-terminal region (amino acids 1–126) of COX-2 interacts
with p53
We then examined whether the interaction between COX-2 and
p53 is involved in the regulation of p53 function. To explore this
possibility, we ﬁrst attempted to determine which part of COX-2
participates in the interaction with p53. COX-2 is composed of 604
amino acids and contains an epidermal growth factor (EGF)-like
domain (amino acids 25–54), a membrane-binding domain (MBD,
amino acids 59–111), and a large catalytic domain. It also contains a
signal sequence targeting the ER at the amino-terminus and an ER
retention signal (STEL) at the carboxy-terminus [2] (Fig. 2A).f the structure of p53 and the deletion mutants used. AD, activation domain; DBD, DNA-
e COX-2-interacting region of p53 by immunoprecipitation assays. Expression vectors for
s indicated. In (B), immunoprecipitationwas carried out using an anti-ﬂag antibody, and
ecipitation was carried out using an anti-COX-2 antibody, and the samples were then
etween p53 and SV40 large T antigen (SV40 LT). Expression vectors for p53 (1 μg), SV40
cells as indicated. Immunoprecipitation was carried out using an anti-SV40 LT antibody,
, SV40 LT and COX-2. (E) COX-2 does not affect the interaction between p53 andMdm-2.
f COX-2were transfected into H1299 cells as indicated. Immunoprecipitationwas carried
blotting with antibodies against p53, Mdm-2 and COX-2. (F) COX-2 inhibits the DNA-
ated. Nuclear extracts were prepared and incubated with 32P-labeled oligonucleotides
ure. The speciﬁc bands of p53-DNA complexes were detected in EMSAs. (G) COX-2 does
ed with p53 (0.5 μg) and an increasing amount (0, 1.25, 2.5 and 5 μg) of COX-2 cDNAs as
CL), cytoplasmic, and nuclear fractions. Tubulin and PARP were used as controls for the
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containing the full-length protein (FL, amino acids 1–604); an amino-
terminal region (N, amino acids 1–126) including the EGF-like domain
and the MBD; a middle region (M, amino acids 127–439); and a
carboxy-terminal region (C, amino acids 440–604) (Fig. 2A). GST pull-
down experiments were carried out using lysates of U2OS cells that
had been treated with doxorubicin to enrich for the endogenous p53
protein. As shown in Fig. 2B, p53 interactedwith GST-COX-2-FL and -N
but not with GST, GST-COX-2-M and -C, suggesting that the region
from amino acids 1 to 126 of COX-2 is involved in the interaction
with p53.
To verify the identity of the p53-interacting region of COX-2 at
cellular levels, we constructed (myc)6-tagged COX-2 deletion
mutant plasmids encoding the FL, N, M, C and the N-truncated
region (ΔN, amino acids 127–604) (Fig. 2A). U2OS cells were
transfected with each myc-COX-2 deletion mutant DNAs and then
treated with doxorubicin, followed by immunoprecipitation experi-
ments using an anti-myc antibody. Endogenous p53 was co-
immunoprecipitated with myc-COX-2-FL and -N but not with myc-
COX-2-M, -C and ΔN (Fig. 2C). This data conﬁrms that the region
from amino acids 1 to 126 of COX-2 is involved in the interaction
with p53.
To examine whether the interaction between COX-2 and p53 is
direct or not, we incubated the GST-COX-2 deletion mutants with
puriﬁed human p53 protein and carried out GST pull-down experi-Fig. 4. COX-2 inhibits the DNA-binding and transcriptional activity of p53 through the p53-int
vectors for p53 (0.5 μg) and an increasing amount (0, 2.5 and 5 μg) of each myc-COX-2 deleti
kept constant by adding an empty vector. Nuclear extracts made from these cells were incuba
antibody was added as a mixture. The speciﬁc bands of p53–DNA complexes and supershi
western blot analysis using antibodies against p53, myc, tubulin and PARP (lower panels). (B
with p53, β-galactosidase, myc-COX-2 deletion mutants or an empty vector (Vt) as indicat
normalized to the β-galactosidase activity. Data represent means±SD (n=6, ⁎⁎pb0.01).ments. We observed that the puriﬁed p53 protein bound to GST-
COX-2-FL and -N but not to GST, GST-COX-2-M and -C (Fig. 2D).
This suggests that COX-2 directly binds to p53 through amino acids
1 to 126.
3.3. COX-2 interacts with the DNA-binding domain of p53
The 393-amino acid p53 protein contains two transactivation
domains designated as AD1 (amino acids 1–42) and AD2 (amino
acids 43–92); a DNA-binding domain (amino acids 102–292); a
tetramerization domain (amino acids 326–356); and a basic domain
(amino acids 364–393) [39]. To determine the region of p53 with
which COX-2 interacts, we constructed ﬂag-tagged p53 deletion
mutant plasmids encoding the full-length protein (FL, amino acids 1–
393), a middle region (M, amino acids 100–290), a carboxy-terminal
region (C, amino acids 290–393), an M-truncated region (ΔM) and an
N-truncated region (ΔN) (Fig. 3A).
H1299 cells were transfected with COX-2 and each ﬂag-p53
deletion mutant DNAs, and immunoprecipitation experiments were
carried out using an anti-ﬂag antibody. The data showed that COX-2
was co-immunoprecipitated with ﬂag-p53-FL, -M and -ΔN but not
with ﬂag-p53-C and -ΔM (Fig. 3B). Reverse immunoprecipitation
experiments using an anti-COX-2 antibody also showed that ﬂag-
p53-FL, -M and -ΔN were co-immunoprecipitated with COX-2, but
ﬂag-p53-C and -ΔM were not (Fig. 3C). Moreover, myc-COX-2-N waseracting region. (A) COX-2-FL and -N inhibit the DNA-binding activity of p53. Expression
on mutant were transfected into Saos-2 cells as indicated. The total amount of DNAwas
ted with 32P-labeled oligonucleotides containing the p53 binding sequence. An anti-p53
fted bands were detected in EMSAs (upper panel). Nuclear extracts were subjected to
and C) COX-2-FL and -N inhibit p53 transcriptional activity. Saos-2 cells were transfected
ed, together with Bax-Luc (B) or PUMA-Luc (C). Luciferase activity was measured and
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These results suggest that the region from amino acids 100 to 290 of
p53, the DNA-binding domain, is involved in the interaction with
COX-2.
The SV40 large T antigen is a viral oncoprotein that is known to
bind to the DNA-binding domain of p53 [40]. To verify that COX-2
interacts with the DNA-binding domain of p53, we asked whether
COX-2 could compete with the SV40 large T antigen for binding to
p53. For this purpose, we transfected H1299 cells with p53, SV40
large T antigen and an increasing amount of COX-2 cDNAs, then
performed immunoprecipitation experiments using an antibody
against the SV40 large T antigen. We observed that COX-2 could
abrogate the interaction between p53 and the SV40 large T antigen
in a dose-dependent manner (Fig. 3D). In contrast, COX-2 did not
affect the interaction between p53 and Mdm-2, which binds to the
transactivation domain of p53 [41] (Fig. 3E). These results strongly
support our data that COX-2 interacts with the DNA-binding domain
of p53.
If COX-2 interacts with the DNA-binding domain of p53, it is
likely that COX-2 interferes with the DNA-binding activity of p53. To
test this possibility, we monitored the DNA-binding activity of p53
by electrophoretic mobility shift assays (EMSAs) using nuclear
extracts made from p53-null Saos-2 cells transfected with p53 and
COX-2 cDNAs. COX-2 abrogated the binding of p53 to DNA oligomers
harboring its target sequence (Fig. 3F). The levels of p53 protein in
whole cell lysates and nuclear extracts were not reduced by COX-2
expression (Fig. 3G), suggesting that COX-2 did not abrogate the
DNA-binding activity of p53 by regulating p53 protein levels or
sequestering p53 in the cytoplasm. Taken together, these results
demonstrate that COX-2 inhibits the DNA-binding activity of p53,
and they further support our data that COX-2 interacts with the
DNA-binding domain of p53.Fig. 5. COX-2 inhibits p53- and genotoxic stress-induced apoptosis through the p53-interac
with Ad-GFP and Ad-COX-2 deletion mutants, followed by infection with Ad-p53 or Ad-GFP
cytometry. Data represent means±SD (n=6, ⁎⁎pb0.01). (B) HMECs were treated as in (A)
cleaved caspase-3, myc and GFP. (C) COX-2-FL and -N inhibit genotoxic stress-induced apo
treatment with doxorubicin (2 μM). Cells were collected, and the sub-G1 cell populationwas
were treated as in (C). Cell lysates were subjected to western blot analysis using antibodies3.4. COX-2 inhibits the DNA-binding and transcriptional activity of p53
through its p53-interacting region
Next, we tested whether COX-2 inhibits the DNA-binding activity
of p53 via the p53-interacting region. Saos-2 cells were transfected
with p53 and each myc-COX-2 deletion mutant DNAs, and the DNA-
binding activity of p53 was monitored by EMSAs. We observed that
the extent of the DNA binding by p53 was substantially decreased by
co-transfectionwithmyc-COX-2-FL and -N but not withmyc-COX-2-M
and -C (Fig. 4A, upper panel). The level of p53 protein in the nuclear
extracts was not reduced by co-expression of myc-COX-2 deletion
mutants (Fig. 4A, lower panels), indicating that myc-COX-2-FL and -N
did not abrogate the binding of p53 to DNA by regulating p53 protein
levels. These data demonstrate that the p53-interacting region of COX-
2 is critical for COX-2's ability to inhibit the DNA-binding activity of
p53, and they further suggest that COX-2 inhibits the DNA-binding
activity of p53 via its physical interaction with p53.
The DNA-binding activity of p53 is essential for its transactivation
function. Therefore, we assessed the effect of the myc-COX-2 deletion
mutants on the transcriptional activity of p53 by using luciferase
reporter assays involving promoters of the p53 target genes, Bax and
PUMA. Saos-2 cells were transfected with p53 and each myc-COX-2
deletion mutant DNAs, together with Bax promoter (Bax-Luc) or
PUMA promoter (PUMA-Luc) fused to a luciferase reporter. Bax and
PUMA promoter activities were increased by ∼15- and ∼2.8-fold,
respectively, by p53, when compared to the control, that is, p53(−)
and myc-COX-2(−). The enhanced promoter activities by p53 were
inhibited by myc-COX-2-FL and -N by more than 75% and 70%,
respectively. In contrast, myc-COX-2-M, -C and -ΔN had no signiﬁcant
effect on the p53-mediated activation of the Bax and PUMA promoter
(Fig. 4B and C). We also observed that myc-COX-2-FL and -N, but not
myc-COX-2-M, -C and -ΔN, inhibited the p53-mediated activation ofting region. (A) COX-2-FL and -N inhibit p53-induced apoptosis. HMECs were infected
. After 24 h, cells were collected and the sub-G1 cell population was measured by ﬂow
. Cell lysates were subjected to western blot analysis using antibodies against p53, p21,
ptosis. HMECs were infected with Ad-GFP or Ad-COX-2 deletion mutants, followed by
measured by ﬂow cytometry. Data represent means±SD (n=6, ⁎⁎pb0.01). (D) HMECs
against p53, p21, cleaved caspase-3, myc and GFP.
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indicate that the p53-interacting region of COX-2 is crucial to COX-2's
ability to inhibit p53 transcriptional activity, and they suggest that
COX-2 inhibits p53 transcriptional activity through a physical
interaction with p53.
3.5. COX-2 inhibits p53- and genotoxic stress-induced apoptosis through
the p53-interacting region
Since the p53-interacting region of COX-2 potently inhibited the
DNA-binding and transcriptional activity of p53, we asked whether
COX-2 might inhibit the pro-apoptotic function of p53 through the
p53-interacting region. For this purpose, we generated adenoviruses
expressingmyc-COX-2 deletionmutants (Ad-COX-2-FL, -N, -M and -C)
and green ﬂuorescent protein (Ad-GFP) as a control, and analyzed the
effects of the COX-2 deletion mutants on apoptosis induced by p53
resulting from infection with recombinant adenoviruses expressing
p53 (Ad-p53).
HMECs were infected with Ad-GFP, Ad-COX-2-FL, -N, -M or -C and
then infected with Ad-p53. After 24 h, cells were harvested, and the
sub-G1 apoptotic cell population was measured by ﬂow cytometry.
The data showed that Ad-p53 dramatically increased the sub-G1 cell
population to 34.3% in control Ad-GFP-infected cells. In contrast, Ad-
COX-2-FL- and -N remarkably reduced the apoptotic population to
11.9% and 9.7%, respectively. Ad-COX-2-M and -C had no signiﬁcantFig. 6. Effect of COX-2 catalytic activity on p53 transcriptional activity. (A) Overexpression of
2, S516Q, or an empty vector (pcDNA3). Cell lysates were subjected to western blot analysis u
panels). PGE2 concentrations were measured in the conditioned medium. Data represent m
transcriptional activity. Saos-2 cells were transfected with p53, β-galactosidase, and an incre
Luc (D). The total amount of DNA was kept constant by adding an empty vector (Suppleme
activity. Data represent means±SD (n=6, ⁎pb0.05, ⁎⁎pb0.01 versus the control; #pb0.05,
analysis using antibodies against COX-2 and β-actin.effect on the apoptotic response when compared to Ad-GFP (-M,
28.5%; -C, 32.1%) (Fig. 5A). In addition, infectionwith Ad-p53 led to an
increase in the level of cleaved caspase-3, whereas the anti-apoptotic
effect of Ad-COX-2-FL- and -N was accompanied by a dramatic
reduction in the amount of cleaved caspase-3 (Fig. 5B), indicating that
Ad-COX-2-FL and -N inhibited the p53-induced apoptosis in a
caspase-3-dependent manner. We also observed that Ad-COX-2-FL
and -N remarkably inhibited the expression of p21 induced by Ad-p53
infection (Fig. 5B), supporting our data that COX-2 inhibits p53
transcriptional activity through the p53-interacting region.
We then examined whether the p53-interacting region of COX-2
inhibits p53-mediated apoptosis induced by DNA damage. HMECs
were infected with Ad-GFP, Ad-COX-2-FL, -N, -M or -C and then
exposed to a genotoxic drug, doxorubicin. The results of ﬂow
cytometry analysis showed that doxorubicin treatment for 24 h
increased the sub-G1 apoptotic cell population to 25.4% in control Ad-
GFP-infected cells. In contrast, Ad-COX-2-FL- and -N dramatically
reduced the percentage of apoptotic cells to 5.9% and 7.7%,
respectively. Neither Ad-COX-2-M nor -C reduced the apoptotic
population signiﬁcantly when compared to Ad-GFP (-M, 21.9%; -C,
24.3%) (Fig. 5C). In addition, administration of doxorubicin increased
the level of cleaved caspase-3, whereas the anti-apoptotic effect of Ad-
COX-2-FL- and -N was accompanied by a dramatic reduction in the
amount of cleaved caspase-3 (Fig. 5D), indicating that Ad-COX-2-FL
and -N inhibited doxorubicin-induced apoptosis in a caspase-3-COX-2 and S516Q in Saos-2 cells. Cells were transfected with expression vectors for COX-
sing antibodies against COX-2 and β-actin. β-actin was used as a loading control (upper
eans±SD (n=6, ⁎⁎pb0.01) (lower panel). (B–D) Effect of COX-2 and S516Q on p53
asing amount of COX-2 or S516Q DNA together with p21-Luc (B), Bax-Luc (C) or PUMA-
ntary Table 1). Luciferase activity was measured and normalized to the β-galactosidase
##pb0.01 versus the corresponding COX-2). Cell lysates were subjected to western blot
1362 E.M. Choi et al. / Biochimica et Biophysica Acta 1793 (2009) 1354–1365dependent manner. We also observed that Ad-COX-2-FL and -N
remarkably inhibited the expression of p21 induced by doxorubicin
treatment (Fig. 5D), suggesting that under genotoxic stress, COX-2
inhibits p53-mediated transcription through the p53-interacting
region.
These results demonstrate that the p53-interacting region of COX-
2 is critical for its inhibition of p53- and genotoxic stress-induced
apoptosis, and they suggest that COX-2 inhibits the pro-apoptotic
function of p53 through a physical interaction with p53.
3.6. Effect of COX-2 catalytic activity on p53 transcriptional activity
To investigate whether the catalytic activity of COX-2 is involved in
the regulation of p53 function, we generated an S516Qmutant of COX-
2 in which the active site serine was substituted with glutamine, then
monitored the production of prostaglandin E2 (PGE2), the major
product of COX-2 catalytic activity. PGE2 production increased by
about 6-fold in Saos-2 cells transfected with wild-type (wt) COX-2
cDNA, whereas it did not increase at all in S516Q-transfected cells,
even though the proteins were expressed at the same level (Fig. 6A).
These results indicated that the S516Q mutant is totally inactive with
regard to catalytic activity, a ﬁnding that is consistent with a previous
report [33].
We then examined the effect of wt COX-2 and S516Q on the
transcriptional activity of p53 by using luciferase reporter assays.
Saos-2 cells were transfected with expression vectors for p53, wt COX-
2 or S516Q, together with the p21 promoter (p21-Luc), Bax promoter
(Bax-Luc) or PUMA promoter (PUMA-Luc). We observed that both wt
COX-2 and S516Q strongly inhibited p53-mediated activation of theFig. 7. Effect of COX-2 catalytic activity on genotoxic stress-induced apoptosis. (A) Overexpre
S516Q at an MOI of 50. After 30 h, cell lysates were prepared and western blot analysis was p
control (upper panels). PGE2 concentrations were measured in the conditioned medium. Dat
overexpression on genotoxic stress-induced apoptosis. HMECs were infected with Ad-GFP, A
collected, and the sub-G1 cell population (M1) wasmeasured by ﬂow cytometry. Data repres
corresponding Ad-COX-2) (left panel). Representative ﬂow cytometry data are shown (right
analysis was performed using antibodies against p53, p21, cleaved caspase-3, COX-2 and GFp21, Bax and PUMA promoters in a dose-dependent manner. We also
observed that S516Q was ∼30% less effective than wt COX-2 in
inhibiting p53 transcriptional activity (Fig. 6B, C, D, Supplementary
Table 1). These results suggest that the inhibitory effect of COX-2 on
p53 transcriptional activity is largely attributable to a catalytic
activity-independent mechanism, with the catalytic activity being
partially involved.
3.7. Effect of COX-2 catalytic activity on genotoxic stress-induced
apoptosis
To further investigate whether the catalytic activity of COX-2 is
responsible for inhibiting the pro-apoptotic function of p53, we
assessed the effect of wt COX-2 and S516Q on genotoxic stress-
induced apoptosis in HMECs. For this purpose, we generated
adenoviruses expressing wt COX-2 (Ad-COX-2), S516Q (Ad-S516Q)
and GFP (Ad-GFP) as a control. The results of western blot analysis
indicated that Ad-COX-2 and Ad-S516Q at a multiplicity of infection
(MOI) of 50 were able to effectively overexpress COX-2 and S516Q,
respectively, in HMECs (Fig. 7A, upper panel). In addition, PGE2
production was increased by about 2.5-fold by Ad-COX-2 infection as
compared with Ad-GFP infection, whereas it was not increased at all
by Ad-S516Q infection (Fig. 7A, lower panel), again conﬁrming that
the S516Q mutant is totally inactive catalytically.
We then infected HMECs with Ad-GFP, Ad-COX-2 or Ad-S516Q and
exposed the cells to doxorubicin. After 24 h, cells were harvested, and
the sub-G1 apoptotic cell populationwasmeasured by ﬂow cytometry.
The data showed that both Ad-COX-2 and Ad-S516Q dramatically
reduced the percentage of apoptotic cells from 23.3% to 12.1% andssion of COX-2 and S516Q in HMECs. Cells were infected with Ad-GFP, Ad-COX-2 or Ad-
erformed using anti-COX-2 and anti-GFP antibodies. GFP was used as an infection dose
a represent means±SD (n=6, ⁎⁎pb0.01) (lower panel). (B) Effect of COX-2 and S516Q
d-COX-2 or Ad-S516Q at an MOI of 50, then treated with doxorubicin (2 μM). Cells were
ent means±SD (n=8, ⁎⁎pb0.01 versus the corresponding Ad-GFP; ##pb0.01 versus the
panels). (C) HMECs were treated as in (B). Cell lysates were prepared and western blot
P.
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S516Q was ∼15% less effective than Ad-COX-2 in inhibiting doxor-
ubicin-induced apoptosis (Fig. 7B and Supplementary Table 2). The
level of cleaved caspase-3 was observed to increase dramatically after
doxorubicin treatment, whereas the anti-apoptotic effect of Ad-COX-2
and Ad-S516Qwas accompanied by amarked reduction in the amount
of cleaved caspase-3 produced (Fig. 7C). These results suggest that
COX-2 inhibits genotoxic stress-induced apoptosis mainly through a
catalytic activity-independent mechanism, with its catalytic activity
being only partially involved.
We also observed that both Ad-COX-2 and Ad-S516Q markedly
reduced the expression of p21 induced by doxorubicin treatment
(Fig. 7C), supporting our data that COX-2 inhibits p53 transcriptional
activity mainly through a catalytic activity-independent mechanism.
4. Discussion
The loss of p53 function as a result of p53 gene mutation or the
functional inactivation of p53 protein itself plays a critical role in
tumorigenesis. COX-2 has been known to promote tumorigenesis, but
the exact mechanisms involved have not been identiﬁed. In this study,
we presented evidence that COX-2 functionally inactivates p53 by
physically interacting with the p53 molecule. We have shown that
COX-2 colocalizes and interacts with p53 in the nucleus under
conditions of genotoxic stress (Fig. 1). COX-2 interacted with the DNA-
binding domain of p53 and interfered with its DNA-binding activity
(Fig. 3). In addition, the p53-interacting region of COX-2 dramatically
inhibited the binding of p53 to DNA, decreased the transcriptional
activity of p53 by N70%, and p53- or genotoxic stress-induced
apoptosis by ∼90% (Figs. 4 and 5).
COX-2 is an ER-resident protein that has both a signal sequence
targeting it to the ER and an ER retention signal. Immunoelectron
microscopy shows that COX-2 resides on the luminal surfaces of the
ER and both the inner and outer nuclear membranes [3]. Sometimes,
however, COX-2 has been found in other cellular compartments. It has
been reported that COX-2 accumulates in the nucleus after adminis-
tration of transforming growth factor α (TGF-α) and phorbol myristic
acetate (PMA) in HCA-7 cells and human diploid ﬁbroblasts (HDFs),
respectively [38,42].We now report that DNA damage also triggers the
nuclear accumulation of COX-2 in various types of human cells
including HMECs, U2OS and HDFs (Fig. 1A–C). In addition, our data
that COX-2 colocalizes and interacts with p53 in the nucleus under
genotoxic conditions suggest that nuclear COX-2 plays an important
role in inhibiting p53 function (Fig. 1D).
At present, it is still uncertain how COX-2 enters the nucleus.
Because COX-2 resides on the luminal surface of the ER and nuclear
membranes, it must ﬁrst be transported across the membranes to
enter the nucleus. Recently, it has been reported that COX-2 is
degraded by the ER-associated degradation (ERAD) system, which
transports ER-resident proteins from the luminal face of the ER to
the cytosolic face across the ER membranes [43]. Therefore, COX-2
might enter the nucleus directly through the nuclear membranes or
from the ER via the cytosol, being transported by as-yet uni-
dentiﬁed molecules across the nuclear or ER membranes. Further
studies are required to elucidate the mechanism of how COX-2
enters the nucleus.
Both the epidermal growth factor (EGF)-like domain and the
membrane-binding domain (MBD) of COX-2 are known to be
important for the molecule's integration into the membranes of the
ER and nuclear envelopes. The EGF-like domain (amino acids 25–54)
is frequently found in integral membrane proteins, and the MBD
(amino acids 59–111) has several aromatic and basic amino acids,
through which COX-2 interacts with one leaﬂet of the lipid bilayer
[2,44]. Our data indicate that p53 interacts with the region of COX-2
that contains the EGF-like domain and theMBD (amino acids 1 to 126)
(Fig. 2), suggesting that a free form of COX-2, rather than amembrane-bound form, is involved in the interactionwith p53. This is compatible
with our ﬁnding that COX-2 interacts with p53 in the nucleus (Fig. 1).
Functional inactivation of p53 is frequently achieved through
physical interactionwith endogenous or exogenous oncoproteins. It is
well known that Mdm-2, an endogenous oncoprotein ampliﬁed in
many types of human cancers, promotes the degradation of p53 and
inhibits p53 transcriptional activity by binding to the transactivation
domain of p53 [41,45]. The adenoviral E1B 55 kDa protein also binds to
the transactivation domain of p53 and thereby inhibits p53 transcrip-
tional activity [46,47]. Hepatitis B virus X protein binds to the DNA-
binding domain and a carboxy-terminal region of p53, thereby
attenuating its DNA-binding and transcriptional activity [48–51].
The SV40 large T antigen binds to the DNA-binding domain of p53 and
also inhibits its DNA-binding and transcriptional activity [40,51]. Here,
we demonstrated that COX-2 interacts with the DNA-binding domain
of p53 and inhibits its DNA-binding and transcriptional activity (Figs.
3 and 4). These data suggest that COX-2 inactivates p53 through a
mechanism that is very similar to that of the SV40 large T antigen, and
they clearly indicate that COX-2 can act as an endogenous oncoprotein
that functionally inactivates p53 through physical interactionwith the
tumor suppressor.
Previously, it has been reported that prostaglandins regulate p53
transcriptional activity. For example, 1 μM concentrations of PGE2
and PGF2α, but not PGD2 and PGI2, can repress p53 transcriptional
activity by 20–50% in MDA-PCa-2b cells [52]. Cyclopentenone
prostaglandins including Δ12-PGJ2, PGA2 and 15-keto PGF2α, but
not 15-keto PGE2 and PGB1, have been shown to reduce p53
transcriptional activity by 10–40% at 10 μM in RKO cells [53]. In
contrast, 0.1 μM concentrations of PGE2 have been found to enhance
p53 transcriptional activity by ∼2.5-fold in human synovial ﬁbro-
blasts [35]. These data suggest that p53 activity can be partially
modulated by COX-2 catalytic activity, but it is controversial whether
the catalytic activity down-regulates or up-regulates p53 activity. We
have now used an active site mutant of COX-2, S516Q, to provide
direct evidence that the catalytic activity of COX-2 partially
contributes to the inhibition of p53 function. The S516Q mutant
was ∼30% less effective than wt COX-2 in inhibiting p53 transcrip-
tional activity and ∼15% less effective in inhibiting genotoxic stress-
induced apoptosis (Figs. 6, 7, Supplementary Table 1 and 2).
Pharmacological inhibitors of COX-2 catalytic activity have been
shown to bind to its catalytic domain, producing conformational
changes in the molecule, particularly in the MBD [2,54]. We have
shown here that COX-2 interacts with p53 through the MBD-
containing region, suggesting that COX-2 inhibitors could affect the
COX-2-p53 interaction by inducing a conformational change in the
p53-interacting region of COX-2. This hypothesis is supported by our
previous report that NS-398, a selective COX-2 inhibitor, can abrogate
the COX-2-p53 interaction [29]. Therefore, COX-2 inhibitors might
affect the tumorigenic process by modulating the COX-2-p53
interaction.
In conclusion, we have now demonstrated that COX-2 inhibits p53-
mediated transcription and apoptosis principally by interacting with
the p53 molecule. Our study suggests that COX-2 functionally
inactivates p53 under genotoxic conditions by forming COX-2-p53
complexes and this property of COX-2 may be one of the mechanisms
by which COX-2 promotes tumorigenesis. Since the majority of this
study has been performed in overexpression systems and in limited
cell types, further studies are required to verify whether COX-2 does
regulate p53 function through a physical interaction in more
physiological and diverse systems.
Acknowledgements
We thank for Dr. H.D. Youn, Dr. J.I. Kim, Dr. J.Y. Lee, and Dr. K.S. Ha
for invaluable DNAs and confocal microscopy. We also thank Dr. B.
Vogelstein for the precious PUMA-Luc. This work was supported by
1364 E.M. Choi et al. / Biochimica et Biophysica Acta 1793 (2009) 1354–1365the Korea Research Foundation Grant funded by the Korean govern-
ment (MOEHRD) (KRF-2005-041-E00054).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbamcr.2009.05.006.
References
[1] W.L. Smith, R.M. Garavito, D.L. DeWitt, Prostaglandin endoperoxide H synthases
(cyclooxygenases)-1 and -2, J. Biol. Chem. 271 (1996) 33157–33160.
[2] R.M. Garavito, M.G. Malkowski, D.L. DeWitt, The structures of prostaglandin
endoperoxide H synthases-1 and -2, Prostaglandins Other Lipid Mediat. 68–69
(2002) 129–152.
[3] A.G. Spencer, J.W. Woods, T. Arakawa, I.I. Singer, W.L. Smith, Subcellular
localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoe-
lectron microscopy, J. Biol. Chem. 273 (1998) 9886–9893.
[4] T.G. Brock, R.W. McNish, M. Peters-Golden, Arachidonic acid is preferentially
metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2, J. Biol.
Chem. 274 (1999) 11660–11666.
[5] H. Koga, S. Sakisaka, M. Ohishi, T. Kawaguchi, E. Taniguchi, K. Sasatomi, M. Harada,
T. Kusaba, M. Tanaka, R. Kimura, Y. Nakashima, O. Nakashima,M. Kojiro, T. Kurohiji,
M. Sata, Expression of cyclooxygenase-2 in human hepatocellular carcinoma:
relevance to tumor dedifferentiation, Hepatology 29 (1999) 688–696.
[6] H.Y. Lim, H.J. Joo, J.H. Choi, J.W. Yi, M.S. Yang, D.Y. Cho, H.S. Kim, D.K. Nam, K.B. Lee,
H.C. Kim, Increased expression of cyclooxygenase-2 protein in human gastric
carcinoma, Clin. Cancer Res. 6 (2000) 519–525.
[7] R.A. Soslow, A.J. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, J. Masferrer, A.T.
Koki, COX-2 is expressed in human pulmonary, colonic, and mammary tumors,
Cancer 89 (2000) 2637–2645.
[8] R. Yoshimura, H. Sano, C. Masuda, M. Kawamura, Y. Tsubouchi, J. Chargui, N.
Yoshimura, T. Hla, S. Wada, Expression of cyclooxygenase-2 in prostate carcinoma,
Cancer 89 (2000) 589–596.
[9] R. Yoshimura, H. Sano, M. Mitsuhashi, M. Kohno, J. Chargui, S. Wada, Expression of
cyclooxygenase-2 in patients with bladder carcinoma, J. Urol. 165 (2001)
1468–1472.
[10] C.H. Liu, S.H. Chang, K. Narko, O.C. Trifan, M.T. Wu, E. Smith, C. Haudenschild, T.F.
Lane, T. Hla, Overexpression of cyclooxygenase-2 is sufﬁcient to induce
tumorigenesis in transgenic mice, J. Biol. Chem. 276 (2001) 18563–18569.
[11] R.D. Klein, C.S. Van Pelt, A.L. Sabichi, J. Dela Cerda, S.M. Fischer, G. Furstenberger, K.
Muller-Decker, Transitional cell hyperplasia and carcinomas in urinary bladders of
transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpres-
sion, Cancer Res. 65 (2005) 1808–1813.
[12] M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, E. Kwong, J.M.
Trzaskos, J.F. Evans, M.M. Taketo, Suppression of intestinal polyposis in Apc
delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2), Cell 87 (1996)
803–809.
[13] C.J. Grubbs, R.A. Lubet, A.T. Koki, K.M. Leahy, J.L. Masferrer, V.E. Steele, G.J. Kelloff,
D.L. Hill, K. Seibert, Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-
induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344
rats, Cancer Res. 60 (2000) 5599–5602.
[14] R.E. Harris, G.A. Alshaﬁe, H. Abou-Issa, K. Seibert, Chemoprevention of breast
cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor, Cancer Res. 60 (2000)
2101–2103.
[15] R.F. Jacoby, K. Seibert, C.E. Cole, G. Kelloff, R.A. Lubet, The cyclooxygenase-2
inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse
model of adenomatous polyposis, Cancer Res. 60 (2000) 5040–5044.
[16] M. Oshima, N. Murai, S. Kargman, M. Arguello, P. Luk, E. Kwong, M.M. Taketo, J.F.
Evans, Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by
rofecoxib, a speciﬁc cyclooxygenase-2 inhibitor, Cancer Res. 61 (2001) 1733–1740.
[17] I.F. Orengo, J. Gerguis, R. Phillips, A. Guevara, A.T. Lewis, H.S. Black, Celecoxib, a
cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin
cancer: a study in the hairless mouse model, Arch. Dermatol. 138 (2002)
751–755.
[18] P.J. Hu, J. Yu, Z.R. Zeng, W.K. Leung, H.L. Lin, B.D. Tang, A.H. Bai, J.J. Sung,
Chemoprevention of gastric cancer by celecoxib in rats, Gut 53 (2004) 195–200.
[19] K.T. Nam, K.B. Hahm, S.Y. Oh, M. Yeo, S.U. Han, B. Ahn, Y.B. Kim, J.S. Kang, D.D. Jang,
K.H. Yang, D.Y. Kim, The selective cyclooxygenase-2 inhibitor nimesulide prevents
Helicobacter pylori-associated gastric cancer development in amousemodel, Clin.
Cancer Res. 10 (2004) 8105–8113.
[20] S.J. Fei, S.D. Xiao, Y.S. Peng, X.Y. Chen, Y. Shi, Chemopreventive effects of rofecoxib
and folic acid on gastric carcinogenesis induced by N-methyl-N'-nitro-N-
nitrosoguanidine in rats, Chin. J. Dig. Dis. 7 (2006) 134–140.
[21] G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, G.B. Gordon, N.
Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, L.K. Su, B. Levin, The effect of
celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis, N.
Engl. J. Med. 342 (2000) 1946–1952.
[22] R.K. Phillips, M.H. Wallace, P.M. Lynch, E. Hawk, G.B. Gordon, B.P. Saunders, N.
Wakabayashi, Y. Shen, S. Zimmerman, L. Godio, M. Rodrigues-Bigas, L.K. Su, J.
Sherman, G. Kelloff, B. Levin, G. Steinbach, A randomized, double blind, placebo
controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal
polyposis in familial adenomatous polyposis, Gut 50 (2002) 857–860.[23] M.D. Castellone, H. Teramoto, B.O. Williams, K.M. Druey, J.S. Gutkind, Prostaglan-
din E2 promotes colon cancer cell growth through a Gs-Axin-β-catenin signaling
axis, Science 310 (2005) 1504–1510.
[24] K. Krysan, K.L. Reckamp, H. Dalwadi, S. Sharma, E. Rozengurt, M. Dohadwala, S.M.
Dubinett, Prostaglandin E2 activates mitogen-activated protein kinase/Erk path-
way signaling and cell proliferation in non-small cell lung cancer cells in an
epidermal growth factor receptor-independent manner, Cancer Res. 65 (2005)
6275–6281.
[25] C. Han, T. Wu, Cyclooxygenase-2-derived prostaglandin E2 promotes human
cholangiocarcinoma cancer cell growth and invasion through EP1 receptor-
mediated activation of the epidermal growth factor receptor and Akt, J. Bio. Chem.
280 (2005) 24053–24063.
[26] B. Vogelstein, D. Lane, A.J. Levine, Surﬁng the p53 network, Nature 408 (2000)
307–310.
[27] P. May, E. May, Twenty years of p53 research: structural and functional aspects of
the p53 protein, Oncogene 18 (1999) 7621–7636.
[28] J.A. Han, J.I. Kim, P.P. Ongusaha, D.H. Hwang, L.R. Ballou, A. Mahale, S.A. Aaronson,
S.W. Lee, P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-
induced apoptosis, EMBO J. 21 (2002) 5635–5644.
[29] E.M. Choi, J.I. Heo, J.Y. Oh, Y.M. Kim, K.S. Ha, J.I. Kim, J.A. Han, COX-2 regulates p53
activity and inhibits DNA damage-induced apoptosis, Biochem. Biophys. Res.
Commun. 328 (2005) 1107–1112.
[30] C.A. Corcoran, Q. He, Y. Huang, M.S. Sheikh, Cyclooxygenase-2 interacts with p53
and interferes with p53-dependent transcription and apoptosis, Oncogene 24
(2005) 1634–1640.
[31] H.Y. Tang, A. Shih, H.J. Cao, F.B. Davis, P.J. Davis, H.Y. Lin, Resveratrol-induced
cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer
cells, Mol. Cancer Ther. 5 (2006) 2034–2042.
[32] V. Band, D. Zajchowski, V. Kulesa, R. Sager, Human papilloma virus DNAs
immortalize normal human mammary epithelial cells and reduce their growth
factor requirements, Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 463–467.
[33] M. Lecomte, O. Laneuville, C. Ji, D.L. DeWitt, W.L. Smith, Acetylation of human
prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin, J. Biol.
Chem. 269 (1994) 13207–13215.
[34] T.C. He, S. Zhou, L.T. da Costa, J. Yu, K.W. Kinzler, B. Vogelstein, A simpliﬁed system
for generating recombinant adenoviruses, Proc. Natl. Acad. Sci. U. S. A. 95 (1998)
2509–2514.
[35] W.H. Faour, Q. He, A. Mancini, D. Jovanovic, J. Antoniou, J.A. Di Battista,
Prostaglandin E2 stimulates p53 transactivational activity through speciﬁc serine
15 phosphorylation in human synovial ﬁbroblasts. Role in suppression of c/EBP/
NF-kappaB-mediated MEKK1-induced MMP-1 expression, J. Biol. Chem. 281
(2006) 19849–19860.
[36] G.Z. Gong, Y.F. Jiang, Y. He, L.Y. Lai, Y.H. Zhu, X.S. Su, HCV NS5A abrogates p53
protein function by interfering with p53-DNA binding, World J. Gastroenterol. 10
(2004) 2223–2227.
[37] L. Qu, S. Huang, D. Baltzis, A.M. Rivas-Estilla, O. Pluquet, M. Hatzoglou, C.
Koumenis, Y. Taya, A. Yoshimura, A.E. Koromilas, Endoplasmic reticulum stress
induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a
pathway involving glycogen synthase kinase-3beta, Genes Dev. 18 (2004)
261–277.
[38] J.Y. Liou, W.G. Deng, D.W. Gilroy, S.K. Shyue, K.K. Wu, Colocalization and
interaction of cyclooxygenase-2 with caveolin-1 in human ﬁbroblasts, J. Biol.
Chem. 276 (2001) 34975–34982.
[39] K.L. Harms, X. Chen, The functional domains in p53 family proteins exhibit both
common and distinct properties, Cell Death Differ. 13 (2006) 890–897.
[40] W. Lilyestrom, M.G. Klein, R. Zhang, A. Joachimiak, X.S. Chen, Crystal structure of
SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a
cellular tumor suppressor, Genes Dev. 20 (2006) 2373–2382.
[41] J.D. Oliner, J.A. Pietenpol, S. Thiagalingam, J. Gyuris, K.W. Kinzler, B. Vogelstein,
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53,
Nature 362 (1993) 857–860.
[42] R.J. Coffey, C.J. Hawkey, L. Damstrup, R. Graves-Deal, V.C. Daniel, P.J. Dempsey, R.
Chinery, S.C. Kirkland, R.N. DuBois, T.L. Jetton, J.D. Morrow, Epidermal growth
factor receptor activation induces nuclear targeting of cyclooxygenase-2,
basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer
cells, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 657–662.
[43] U.R. Mbonye, M. Wada, C.J. Rieke, H.Y. Tang, D.L. Dewitt, W.L. Smith, The 19-amino
acid cassette of cyclooxygenase-2 mediates entry of the protein into the
endoplasmic reticulum-associated degradation system, J. Biol. Chem. 281
(2006) 35770–35778.
[44] Z. MirAfzali, J.R. Leipprandt, J.L. McCracken, D.L. DeWitt, Topography of the
prostaglandin endoperoxide H2 synthase-2 in membranes, J. Biol. Chem. 281
(2006) 28354–28364.
[45] M.H. Kubbutat, S.N. Jones, K.H. Vousden, Regulation of p53 stability by Mdm2,
Nature 387 (1997) 299–303.
[46] M.E. Martin, A.J. Berk, Adenovirus E1B 55K represses p53 activation in vitro,
J. Virol. 72 (1998) 3146–3154.
[47] L.Y. Zhao, D. Liao, Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B
55-kiloDalton oncoprotein is required for inhibition of p53-mediated apoptosis,
J. Virol. 77 (2003) 13171–13181.
[48] X.W.Wang, K. Forrester, H. Yeh, M.A. Feitelson, J.R. Gu, C.C. Harris, Hepatitis B virus
X protein inhibits p53 sequence-speciﬁc DNA binding, transcriptional activity, and
association with transcription factor ERCC3, Proc. Natl. Acad. Sci. U. S. A. 91 (1994)
2230–2234.
[49] L.W. Elmore, A.R. Hancock, S.F. Chang, X.W. Wang, S. Chang, C.P. Callahan, D.A.
Geller, H. Will, C.C. Harris, Hepatitis B virus X protein and p53 tumor suppressor
1365E.M. Choi et al. / Biochimica et Biophysica Acta 1793 (2009) 1354–1365interactions in the modulation of apoptosis, Proc. Natl. Acad. Sci. U. S. A. 94 (1997)
14707–14712.
[50] Y. Lin, T. Nomura, T. Yamashita, D. Dorjsuren, H. Tang, S. Murakami, The
transactivation and p53-interacting functions of hepatitis B virus X protein are
mutually interfering but distinct, Cancer Res. 57 (1997) 5137–5142.
[51] J.A. Mietz, T. Unger, J.M. Huibregtse, P.M. Howley, The transcriptional transactiva-
tion function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16
E6 oncoprotein, EMBO J. 11 (1992) 5013–5020.
[52] X.H. Liu, A. Kirschenbaum, K. Yu, S. Yao, A.C. Levine, Cyclooxygenase-2 suppresses
hypoxia-induced apoptosis via a combination of direct and indirect inhibitionof p53 activity in a human prostate cancer cell line, J. Biol. Chem. 280 (2005)
3817–3823.
[53] P.J. Moos, K. Edes, P. Cassidy, E. Massuda, F.A. Fitzpatrick, Electrophilic
prostaglandins and lipid aldehydes repress redox-sensitive transcription factors
p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin
reductase, J. Biol. Chem. 278 (2003) 745–750.
[54] T. Smith, J. McCracken, Y.K. Shin, D. DeWitt, Arachidonic acid and nonsteroidal
anti-inﬂammatory drugs induce conformational changes in the human prosta-
glandin endoperoxide H2 synthase-2 (cyclooxygenase-2), J. Biol. Chem. 275
(2000) 40407–40415.
